Close Menu
  • Home
  • Vaccines
  • Politics
  • Health
  • Tech
  • Sports
  • Research
  • Fitness
  • Careers
What's Hot

Health Canada approves Novartis’ KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

Sheriff, county lawyer seeking mental health funds at Minnesota State Capitol

Chronic absences have not disappeared. Research shows that poor children are most hurt.

Facebook X (Twitter) Instagram
subjectional.com
Subscribe
  • Home
  • Vaccines
  • Politics
  • Health
  • Tech
  • Sports
  • Research
  • Fitness
  • Careers
subjectional.com
Home » UK biotech startup raises $100 million to develop next-generation vaccine for respiratory viruses
Vaccines

UK biotech startup raises $100 million to develop next-generation vaccine for respiratory viruses

Paul E.By Paul E.September 23, 2024No Comments2 Mins Read
Share Facebook Twitter Pinterest Copy Link Telegram LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


The vaccine market may be competitive, but London-based Vicebio is looking to carve out a unique position for itself within it: The startup today announced it has raised $100 million in Series B funding to develop a next-generation vaccine against respiratory viruses.

Vicebio aims to deliver a vaccine that is highly effective, easy to manufacture, and ready to use in a prefilled syringe, and the key to achieving this outcome is the use of a novel approach called molecular clamp technology.

The technology was first invented by a research group led by Paul Young, Daniel Watterson and Keith Chappell at the University of Queensland in Australia and has been exclusively licensed to Vicebio through the university’s commercialization arm, Uniquest.

According to the startup, the molecular clamp has the ability to “fix” proteins on the surface of the virus in a “perfusate” form before the virus attaches to a cell.

Back in business at the TNW Conference

It’s time to set your goals and budget for next year. Get your 2 tickets now and save €€€ with this super early bird price. Limited offer.

This effect could stimulate a stronger immune response, and it might also enable the startup to simplify the manufacturing process, making the vaccine more cost-effective.

Vaccines against multiple strains of the virus

Viseibio plans to use part of the funding to advance Phase 1 clinical trials of its first vaccine, VXB-241, which targets both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), which particularly affect elderly and immunocompromised patients.

The company also plans to use the funding to expand its vaccine portfolio, which includes developing another combo vaccine targeting respiratory syncytial virus, hMPV, and parainfluenza virus 3 (PIV3).

Medtech venture capital firm TCGX led the funding round, with participation from Goldman Sachs Alternatives, Avolo Ventures, venBio, Uniquest and founding investor Medixy.

Vicebio is focused on easy-to-produce polyvalent vaccines (vaccines that target multiple virus strains simultaneously), which could give the startup an edge in a competitive market.

This is especially true for the company’s VXB-241 vaccine, as there are currently no commercially available vaccines that target both RSV and hMPV, but the company will have to compete with Icosavax, which was recently acquired by AstraZeneca.

Icosavax is progressing into Phase 2 with its RSV/hMPV vaccine, and Vicebio expects Phase 1 results for VXB-241 in mid-2025.



Source link

Follow on Google News Follow on Flipboard
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Copy Link
Previous ArticleSmoking cessation drugs, latest information on bird flu
Next Article New study finds that people who use health and fitness apps spend more time exercising
Paul E.
  • Website

Related Posts

Kentucky leaders emphasize whooping cough vaccination

October 31, 2024

Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial

October 31, 2024

Trust is important, but increasing vaccination rates also requires three things

October 31, 2024
Leave A Reply Cancel Reply

Latest Posts

Health Canada approves Novartis’ KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

Sheriff, county lawyer seeking mental health funds at Minnesota State Capitol

Chronic absences have not disappeared. Research shows that poor children are most hurt.

Transport Secretary reveals overhaul of aging pneumatic transport systems

Latest Posts

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Welcome to Subjectional!

At Subjectional, we believe that informed opinions are the foundation of a vibrant society. Our mission is to provide insightful, engaging, and balanced information across a diverse range of topics that matter to you. Whether you’re interested in the latest developments in health, navigating the complexities of politics, staying updated on sports, exploring technological advancements, or advancing your career, we’ve got you covered.

Facebook X (Twitter) Instagram Pinterest YouTube

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Facebook X (Twitter) Instagram Pinterest
  • Home
  • About Us
  • Advertise with Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
© 2025 subjectional. Designed by subjectional.

Type above and press Enter to search. Press Esc to cancel.